Abstract
Measurement of serum free light chains (FLC) is an important part of the diagnosis of monoclonal gammopathies.
Together with serum protein electrophoresis and immunofixation/immunotyping, FLC measurement is part of international guidelines, notably for the aid of diagnosis and monitoring of patients with multiple myeloma. FLC testing is also used for the aid of diagnosis and monitoring of patients with AL Amyloidosis.
This workshop recorded during the 25th WorldLab / EuromedLab (2023) focuses on the clinical use of Free Light Chains for Multiple Myeloma and AL Amyloidosis.
Pr. Palladini reviews the different international guidelines and recommendations about FLC testing and reminds the cut-off commutability (« 20 » and « 100 » ratios) between Sebia assay and a predicate method, recently published by Willrich M.A.V et al., in 2022.
Speaker
Free Light Chains* (FLC)
The next generation Free Light Chain Assay.
* Under Product Registration approval
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.